| 4.9 0.22 (4.7%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.22 | 1-year : | 7.27 |
| Resists | First : | 5.32 | Second : | 6.22 |
| Pivot price | 4.38  |
|||
| Supports | First : | 4.36 | Second : | 3.76 |
| MAs | MA(5) : | 4.6 |
MA(20) : | 4.36 |
| MA(100) : | 4.26 |
MA(250) : | 2.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.4 |
D(3) : | 61.6 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 5.69 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRLD ] has closed below upper band by 16.5%. Bollinger Bands are 18% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.76 - 4.78 | 4.78 - 4.8 |
| Low: | 4.42 - 4.44 | 4.44 - 4.46 |
| Close: | 4.65 - 4.68 | 4.68 - 4.72 |
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Fri, 31 Jul 2026
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? - finance.yahoo.com
Wed, 29 Jul 2026
PRLD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Sun, 26 Jul 2026
PRLD|Prelude Therapeutics Inc|Price:4.665|Chg%:+0.125 - TradingKey
Fri, 24 Jul 2026
Prelude Therapeutics Incorporated Revenue Breakdown – NASDAQ:PRLD - TradingView
Fri, 17 Jul 2026
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - finance.yahoo.com
Sat, 16 May 2026
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 64.8 (%) |
| Shares Short | 3,290 (K) |
| Shares Short P.Month | 1,790 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | 0 % |
| Operating Margin | -309.6 % |
| Return on Assets (ttm) | -39.7 % |
| Return on Equity (ttm) | -95.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -4.91 |
| PEG Ratio | 0 |
| Price to Book value | 6.71 |
| Price to Sales | 19.02 |
| Price to Cash Flow | -7.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|